| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/BJH.14181 |
| P698 | PubMed publication ID | 27293194 |
| P2093 | author name string | Lei Gao | |
| Lia Gore | |||
| Jyoti Sharma | |||
| Luciano J Costa | |||
| Farrukh T Awan | |||
| Joanne Lager | |||
| P2860 | cites work | A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma | Q24607479 |
| Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 | ||
| The PI3K pathway as drug target in human cancer | Q24632283 | ||
| mTOR signaling in growth control and disease | Q24634174 | ||
| Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma | Q26865645 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 | ||
| Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
| PI3K and cancer: lessons, challenges and opportunities | Q30080017 | ||
| Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma | Q33388177 | ||
| Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma | Q33413834 | ||
| MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies | Q33419789 | ||
| PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma | Q33690142 | ||
| Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia | Q34009003 | ||
| Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium | Q34488779 | ||
| PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors | Q34606526 | ||
| A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). | Q34663617 | ||
| PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances | Q36516932 | ||
| Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia | Q37037294 | ||
| PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma | Q37049376 | ||
| Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention | Q37448352 | ||
| Target of rapamycin signaling in leukemia and lymphoma | Q37786446 | ||
| Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway | Q38078784 | ||
| Targeting pathological B cell receptor signalling in lymphoid malignancies | Q38085501 | ||
| Many roads from mTOR to eIF4F. | Q38122222 | ||
| Signaling pathways in lymphoma: pathogenesis and therapeutic targets | Q38150876 | ||
| Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor | Q38170076 | ||
| Management of adverse events associated with idelalisib treatment: expert panel opinion | Q38366294 | ||
| Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. | Q38957093 | ||
| The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells | Q39353496 | ||
| Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab | Q39426629 | ||
| Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib | Q39700483 | ||
| Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma | Q39805170 | ||
| Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase | Q40156585 | ||
| Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies | Q42320922 | ||
| High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy | Q43143099 | ||
| Revised response criteria for malignant lymphoma | Q47582438 | ||
| Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly | Q54316519 | ||
| Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. | Q55062120 | ||
| Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors | Q58614417 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 55-65 | |
| P577 | publication date | 2016-06-13 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies | |
| P478 | volume | 175 |
| Q89599313 | Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? |
| Q92258777 | Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology |
| Q92035420 | PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival |
| Q55010628 | Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. |
| Q46675870 | Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience |
Search more.